Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mirna Therapeutics, a wholly owned subsidiary of Asuragen and a biopharmaceutical R&D company, and the University of California, San Francisco have entered into a collaboration agreement to evaluate the capacity of specific microRNAs to reduce or eliminate tumors in mouse models of cancer.
Subscribe to our email newsletter
The collaboration will include studies of cancer-related microRNAs that were discovered at both Mirna and University of California, San Francisco (UCSF) as well as small RNAs that will be identified in research using mouse and cell models from UCSF.
Matt Winkler, CEO of Mirna, said: “We are very excited about the potential of miRNAs as therapeutic agents and look forward to verifying that the small RNAs can be used to treat patients with cancer. Collaborating with a leading institution like UCSF will ensure rigorous testing of therapeutic miRNAs using the most advanced cancer animal models.”